Stacks & Bundles

Skip to results list

Filters

8 items

Filter

Research Peptide Stacks for Sale UK | Peptide Bundles Overview

This collection groups research-grade peptides into stacks that appear together repeatedly in published preclinical literature — not marketing pairings. Each bundle is assembled around compound combinations that have been co-studied in animal models or in-vitro systems because their pathway targets are complementary or overlapping. BPC-157 and TB-500 are studied together in tissue-repair models. GHRP-2 and CJC-1295 DAC are studied together in GH-axis research (GHS-R1a + GHRH-receptor). Semax and Selank are studied together in neuropeptide research.

Every vial in every bundle is manufactured to the same ≥98% HPLC purity standard, identity-confirmed by mass spectrometry, and shipped with a batch-specific certificate of analysis. UK supply, domestic dispatch.

Sold for research use only. Not for human consumption. Not for therapeutic use.

Why Are Research Peptides Studied in Combination?

Most biological pathways involve multiple parallel or sequential steps. Preclinical research designs frequently combine compounds so that different steps in the same pathway — or different receptors within the same signalling family — can be probed simultaneously. In the published literature, combination studies are common in GH-axis research, tissue-repair models, GLP-1 receptor pharmacology and melanocortin studies.

Combination research designs typically fall into three patterns. First, additive receptor activation: GHRP-2 (GHS-R1a agonist) and CJC-1295 DAC (GHRH-receptor agonist) act on separate receptors within the GH-axis and are studied together in animal models of pulsatile GH secretion. Second, sequential-phase coverage: BPC-157 (cytoprotection, VEGF-mediated angiogenesis) and TB-500 (actin regulation, cell migration) target different phases of the repair sequence in preclinical tissue-injury models. Third, parallel-mechanism comparison: multiple compounds acting through distinct pathways are studied together so that researchers can isolate mechanism-specific effects.

The bundles below are grouped along these lines — reflecting how the compounds are co-studied in published research.

Research Stacks — Quick Reference

Tissue Repair Research Stacks

Injury Recovery Research Stack (BPC-157 10mg + TB-500 10mg) — the most co-studied tissue-repair pairing in the preclinical literature. In published animal models, BPC-157 has been studied for cytoprotection and VEGF-pathway angiogenesis, while TB-500 — a synthetic fragment of Thymosin Beta-4 — has been studied for actin regulation and cell-migration signalling. The two compounds target distinct phases of the repair sequence in preclinical models, which is why they appear together in combination-research designs.

View Injury Recovery Research Stack →

Wolverine Recovery Research Stack (BPC-157 + TB-500 + Tirzepatide) — combines the tissue-repair pairing above with a dual GLP-1 / GIP receptor agonist (Tirzepatide) for researchers investigating the intersection between metabolic-pathway signalling and tissue-repair models. Relevant to preclinical designs examining glucose homeostasis, incretin-receptor activation, and repair-phase outcomes together.

Note: Tirzepatide is a prescription-only medicine (POM) in the UK — supplied strictly as a research chemical for in-vitro and preclinical laboratory work. Not for human use.

View Wolverine Recovery Research Stack →

GH Axis Research Stack — GHS-R1a + GHRH-Receptor Combination

GHRP-2 (a GHS-R1a/ghrelin-receptor agonist) and CJC-1295 DAC (a long-acting GHRH-receptor agonist bound to a serum protein carrier for extended half-life) are among the most frequently co-studied GH-axis compounds in the preclinical literature. In animal models, the pairing has been examined for additive effects on pulsatile GH secretion via activation of two separate hypothalamic-pituitary receptors.

Published preclinical studies have documented that combined GHRP-plus-GHRH activation produces GH secretion patterns greater than either compound alone in animal models — one of the more consistently reported findings in the GH-axis research literature. Relevant to researchers studying GH secretion pharmacology, IGF-1 signalling, receptor desensitisation, or GHS-R1a versus GHRH-receptor selectivity.

View GH Optimisation Research Stack →

Body Composition Research Stacks

Body Composition Research Stack (HGH Fragment 176-191 + AOD-9604) — two structurally related C-terminal growth-hormone fragments studied in adipocyte-pathway research. HGH Fragment 176-191 is the unmodified C-terminal region; AOD-9604 is the engineered variant with an additional tyrosine residue. Both have been examined in preclinical models for effects on adipocyte lipolysis pathways. Studied together in comparative-mechanism research designs.

View Body Composition Research Stack →

Metabolic Research Stack (Tirzepatide + Tesamorelin + AOD-9604) — three compounds targeting distinct receptor systems within metabolic research. Tirzepatide is a dual GLP-1 / GIP receptor agonist. Tesamorelin is a GHRH-receptor agonist examined in visceral-adipose-tissue research. AOD-9604 targets adipocyte pathways independently of the GH axis. Grouped for parallel-mechanism research comparison.

Note: Tirzepatide is a prescription-only medicine (POM) in the UK — supplied strictly as a research chemical for in-vitro and preclinical laboratory work. Not for human use.

View Metabolic Research Stack →

GLP-1 Research Stack — anchored on Semaglutide, a long-acting GLP-1 receptor agonist that is the most extensively studied compound in the GLP-1 receptor pharmacology literature. For preclinical research designs investigating GLP-1 receptor activation, satiety signalling and metabolic pathway modulation in animal and cell models.

Note: Semaglutide is a prescription-only medicine (POM) in the UK — supplied strictly as a research chemical for in-vitro and preclinical laboratory work. Not for human use.

View GLP-1 Research Stack →

Cognitive Research Stack — BDNF and GABAergic Pathway Combination

Semax and Selank are Russian-developed heptapeptides with over four decades of combined published preclinical literature. In animal models, both compounds have been documented to cross the blood-brain barrier — an unusual property in peptide research, which makes them frequently used as reference tools in neuropeptide studies.

The two compounds are studied in complementary — not overlapping — pathway research. Semax is examined for effects on BDNF expression and neurotrophic signalling in animal models. Selank is examined for GABAergic-pathway modulation and anxiolytic signalling in animal models. Their frequent co-appearance in published research reflects the complementary nature of these two neuropeptide pathways.

View Cognitive Research Stack →

Longevity Research Stack — Telomerase, Epigenetic and Mitochondrial-Peptide Combination

Three compounds representing three distinct pathway categories in cellular-longevity research. Grouped for parallel-mechanism preclinical research designs.

Epithalon — a synthetic tetrapeptide studied in the telomerase-activation and telomere-length literature since the 1980s. GHK-Cu — a copper-binding tripeptide examined for effects on gene expression across an extensive set of human genes in cell-culture studies. MOTS-c — a mitochondrial-derived peptide (MDP) encoded in the mitochondrial genome, examined in the mitochondrial-signalling and cellular stress-response literature (see Nature Aging, 2021).

Three separate pathway targets in one bundle for researchers designing parallel-mechanism comparisons in cellular-longevity models.

View Longevity Research Stack →

Common Research Questions — Which Stack for Which Research Area?

How Are These Research Bundles Grouped?

Combinations in this collection are grouped on the basis of how the compounds appear together in the published preclinical literature — additive receptor-activation studies, sequential-phase pathway coverage, or parallel-mechanism comparisons. This is intended to reflect real research groupings, not arbitrary marketing bundles.

Every vial in every stack is subject to the same manufacturing standard: ≥98% HPLC purity, identity confirmed by mass spectrometry, batch-specific certificate of analysis. Purity applies to every compound in a combination — impurity in one vial can compromise an entire research dataset, which is why bundle pricing does not override quality-control standards.

Why Buy Research Peptide Stacks from Pure Grade Labs

  • ✓  ≥98% HPLC purity — independently tested on every vial in every stack
  • ✓  Batch-specific certificate of analysis — QR code on each vial links to COA
  • ✓  Identity confirmed by mass spectrometry — every batch, no exceptions
  • ✓  UK supply — domestic dispatch
  • ✓  Bacteriostatic water available separately for laboratory reconstitution

For Research Use Only. All compounds and stacks in this collection are supplied strictly as research chemicals for in-vitro and preclinical laboratory research. Not for human consumption, self-administration, therapeutic use, cosmetic use, or use in food. No medical claims are made or implied. Semaglutide, Tirzepatide and Retatrutide are prescription-only medicines (POM) in the UK — included in relevant research stacks strictly for laboratory research purposes. Researchers are responsible for compliance with all applicable laws, including the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971 and the Psychoactive Substances Act 2016. Products are not tested on animals as finished consumer products.